55.84
-0.28 (-0.50%)
| Previous Close | 56.12 |
| Open | 55.24 |
| Volume | 602,331 |
| Avg. Volume (3M) | 507,557 |
| Market Cap | 3,431,764,480 |
| Price / Sales | 33.30 |
| Price / Book | 339.97 |
| 52 Weeks Range | |
| Earnings Date | 20 Feb 2025 - 24 Feb 2025 |
| Profit Margin | -230.11% |
| Operating Margin (TTM) | -131.98% |
| Diluted EPS (TTM) | -4.32 |
| Quarterly Revenue Growth (YOY) | 47.80% |
| Total Debt/Equity (MRQ) | 74.18% |
| Current Ratio (MRQ) | 3.49 |
| Operating Cash Flow (TTM) | -124.42 M |
| Levered Free Cash Flow (TTM) | -143.16 M |
| Return on Assets (TTM) | -46.24% |
| Return on Equity (TTM) | -147.90% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Rhythm Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.38 |
|
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.53% |
| % Held by Institutions | 115.30% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (Canaccord Genuity, 43.27%) | Buy |
| Median | 69.00 (23.57%) | |
| Low | 52.00 (B of A Securities, -6.88%) | Hold |
| Average | 68.56 (22.78%) | |
| Total | 8 Buy, 1 Hold | |
| Avg. Price @ Call | 56.86 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 23 Dec 2024 | 69.00 (23.57%) | Buy | 56.04 |
| 04 Dec 2024 | 69.00 (23.57%) | Buy | 60.37 | |
| JMP Securities | 23 Dec 2024 | 75.00 (34.31%) | Buy | 56.04 |
| Oppenheimer | 20 Dec 2024 | 76.00 (36.10%) | Buy | 56.12 |
| Goldman Sachs | 05 Dec 2024 | 66.00 (18.19%) | Buy | 57.82 |
| Canaccord Genuity | 19 Nov 2024 | 80.00 (43.27%) | Buy | 59.97 |
| 06 Nov 2024 | 80.00 (43.27%) | Buy | 62.65 | |
| Needham | 06 Nov 2024 | 64.00 (14.61%) | Buy | 62.65 |
| 30 Oct 2024 | 55.00 (-1.50%) | Buy | 49.54 | |
| TD Cowen | 06 Nov 2024 | 65.00 (16.40%) | Buy | 62.65 |
| Guggenheim | 21 Oct 2024 | 70.00 (25.36%) | Buy | 50.19 |
| B of A Securities | 14 Oct 2024 | 52.00 (-6.88%) | Hold | 50.24 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |